Apollomics, Inc.(APLM)Earnings, Financials & Key Ratios

APLM•NASDAQ

$20.80

Price updated Jun 27, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryOncology Therapeutics Developers

AboutApollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.Show more

Revenue$9M+4192.9%
EBITDA-$9M+78.1%
Net Income-$11M+79.7%
EPS (Diluted)-7.57+85.7%
Gross Margin97%-3.0%
EBITDA Margin-108.45%+99.5%
Operating Margin-111.45%+99.5%
Net Margin-128.69%+99.5%
ROE-1305.37%-458.6%

APLM Price & Volume

Apollomics, Inc. (APLM) stock price & volume — 10-year historical chart

Loading chart...

Persistent Clinical Burn Threatens Operational Liquidity Runway

Investment Thesis • Updated 2024Q4

VerdictNegative

Growth:Mixed

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Imminent liquidity exhaustion

Key Thesis Takeaways

Apollomics faces a precarious financial outlook as its oncology pipeline development continues to outpace its ability to generate sustainable commercial revenue, evidenced by a $700.8 million accumulated deficit in retained earnings.
The company's reliance on sporadic milestone payments and external financing creates significant volatility, while the rapid erosion of its asset base from $123.4 million in 2021 to $13.1 million in 2024Q4 suggests an urgent need for strategic capital infusion.
Investors should monitor the firm's ability to manage its $9.8 million cash position against ongoing quarterly R&D expenses that have historically hovered near $17 million.

Verdict Logic

the company's acute liquidity crisis, evidenced by a dwindling cash balance of only $9.8 million against substantial ongoing clinical development costs, presents an imminent risk of further dilutive financing.

APLM Growth Metrics

Apollomics, Inc. (APLM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years35.84%

3 Years197.44%

TTM213.54%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM32.52%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-3727.08%

Return on Capital

10 Years-106.93%

5 Years-136.06%

3 Years-196.84%

Last Year-311.25%

Latest APLM News

Recent stock market news and headlines for Apollomics, Inc. (APLM)

GlobeNewsWire·5 days ago

Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia

FOSTER CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it has received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated June 18, 2026 stating that the Company is not in compliance with the requirement to maintain a minimum Market Value of Listed Securities (“MVLS”) of $35 million as set forth under Nasdaq Listing Rule for continued listing on The Nasdaq Capital Market.

Peers Comparison

Key metrics vs top competitors for Apollomics, Inc. (APLM)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
APLMApollomics, Inc.Current	$20.80	$22.95M	-2.75	4192.93%	-128.69%	-1305.37%	—
IMVTImmunovant, Inc.	$38.85	$7.98B	-14.03	—	—	-68.16%	—
TPVGTriplePoint Venture Growth BDC Corp.	$4.70	$190.82M	3.85	36.55%	-19.55%	-3.39%	—
AGENAgenus Inc.	$3.03	$126.18M	-891.18	10.37%	52.16%	—	—
AGIOAgios Pharmaceuticals, Inc.	$37.90	$2.25B	-5.32	48.03%	-639.84%	-34.11%	—
MGNXMacroGenics, Inc.	$4.81	$305.74M	-4.08	0.78%	-44.79%	-147.8%	—

Compare APLM vs Peers

Apollomics, Inc. (APLM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs IMVT

Most directly comparable listed peer for APLM.

Scale Benchmark

vs IQV

Larger-name benchmark to compare APLM against a more recognizable public peer.

Peer Set

Compare Top 5

vs IMVT, TPVG, AGEN, AGIO

Get notified when APLM posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

APLM Frequently Asked Questions

Apollomics, Inc. (APLM) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Apollomics, Inc.'s revenue?

Apollomics, Inc. (APLM) reported $1.0M in revenue for fiscal year 2025.

How fast is Apollomics, Inc. growing?

Apollomics, Inc. (APLM) grew revenue by 4192.9% over the past year. This is strong growth.

Is APLM profitable?

Apollomics, Inc. (APLM) reported a net loss of $226.5M for fiscal year 2025.

Dividend & Returns

What is APLM's return on equity?

Apollomics, Inc. (APLM) has a return on equity (ROE) of -1305.4%. Negative ROE indicates the company is unprofitable.

What is Apollomics, Inc.'s free cash flow?

Apollomics, Inc. (APLM) had negative free cash flow of $72.0M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in APLM back in 2019?

Total return calculator · dividends reinvested · 7+ years of data

See returns →

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

APLMApollomics, Inc.Current

$20.80

$22.95M

-2.75

4192.93%

-128.69%

-1305.37%

—

IMVTImmunovant, Inc.

$38.85

$7.98B

-14.03

—

-68.16%

—

TPVGTriplePoint Venture Growth BDC Corp.

$4.70

$190.82M

3.85

36.55%

-19.55%

-3.39%

—

AGENAgenus Inc.

$3.03

$126.18M

-891.18

10.37%

52.16%

—

AGIOAgios Pharmaceuticals, Inc.

$37.90

$2.25B

-5.32

48.03%

-639.84%

-34.11%

—

MGNXMacroGenics, Inc.

$4.81

$305.74M

-4.08

0.78%

-44.79%

-147.8%

—